A/S Genmab Acquires 15,710 Shares of Merus (NASDAQ:MRUS) Stock

Posted by ABMN Staff on Dec 31st, 2025

Merus N.V. (NASDAQ:MRUS – Get Free Report) major shareholder A/S Genmab bought 15,710 shares of the stock in a transaction on Monday, December 22nd. The shares were acquired at an average price of $97.00 per share, with a total value of $1,523,870.00. Following the purchase, the insider owned 72,028,775 shares of the company’s stock, valued at $6,986,791,175. The trade was a 0.02% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

A/S Genmab also recently made the following trade(s):

On Monday, December 29th, A/S Genmab purchased 1,052,806 shares of Merus stock. The stock was acquired at an average cost of $97.00 per share, with a total value of $102,122,182.00.
On Friday, December 26th, A/S Genmab acquired 2,978 shares of Merus stock. The shares were acquired at an average cost of $97.00 per share, with a total value of $288,866.00.
On Friday, December 26th, A/S Genmab acquired 142,610 shares of Merus stock. The shares were acquired at an average price of $97.00 per share, for a total transaction of $13,833,170.00.
On Wednesday, December 24th, A/S Genmab bought 96,082 shares of Merus stock. The stock was acquired at an average cost of $97.00 per share, for a total transaction of $9,319,954.00.
On Tuesday, December 23rd, A/S Genmab bought 561,042 shares of Merus stock. The stock was bought at an average price of $97.00 per share, with a total value of $54,421,074.00.
On Friday, December 19th, A/S Genmab bought 66,264 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, with a total value of $6,427,608.00.
On Thursday, December 18th, A/S Genmab purchased 212,177 shares of Merus stock. The stock was bought at an average cost of $97.00 per share, for a total transaction of $20,581,169.00.
On Wednesday, December 17th, A/S Genmab acquired 150,795 shares of Merus stock. The shares were bought at an average price of $97.00 per share, with a total value of $14,627,115.00.
On Tuesday, December 16th, A/S Genmab bought 120,752 shares of Merus stock. The stock was bought at an average cost of $97.00 per share, for a total transaction of $11,712,944.00.

Merus Stock Performance

MRUS stock opened at $90.00 on Wednesday. Merus N.V. has a 1 year low of $33.19 and a 1 year high of $97.14. The stock has a market capitalization of $6.83 billion, a price-to-earnings ratio of -16.98 and a beta of 1.06. The stock’s fifty day moving average is $95.69 and its two-hundred day moving average is $78.00.

Institutional Investors Weigh In On Merus

A number of institutional investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC boosted its stake in Merus by 12.3% during the 3rd quarter. Avoro Capital Advisors LLC now owns 3,542,500 shares of the biotechnology company’s stock valued at $333,526,000 after purchasing an additional 386,945 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its holdings in shares of Merus by 99.4% in the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company’s stock valued at $141,831,000 after buying an additional 1,679,777 shares during the period. Holocene Advisors LP boosted its stake in Merus by 18.8% during the second quarter. Holocene Advisors LP now owns 2,225,241 shares of the biotechnology company’s stock valued at $117,048,000 after buying an additional 351,616 shares in the last quarter. Westfield Capital Management Co. LP grew its holdings in Merus by 4.4% during the third quarter. Westfield Capital Management Co. LP now owns 2,132,489 shares of the biotechnology company’s stock worth $200,774,000 after acquiring an additional 90,101 shares during the period. Finally, Woodline Partners LP raised its position in Merus by 8.5% in the third quarter. Woodline Partners LP now owns 1,674,167 shares of the biotechnology company’s stock worth $157,623,000 after acquiring an additional 131,267 shares in the last quarter. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Key Stores Impacting Merus

Here are the key news stories impacting Merus this week:

Positive Sentiment: A/S Genmab (a major shareholder) has accumulated large blocks of Merus stock across Dec. 16–29, including a reported 1,052,806‑share purchase on Dec. 29 at ~$97 per share — increasing its stake and signaling strong insider/acquirer conviction. This sizeable, repeated buying can be interpreted as bullish support under the shares. SEC Ownership Filing
Positive Sentiment: Large institutional investors have also added positions in recent quarters (e.g., Paradigm Biocapital, Magnetar, Ameriprise), indicating continued institutional interest that can support the longer‑term valuation case. MarketBeat Institutional Ownership
Neutral Sentiment: Trading of MRUS was temporarily halted with a “news pending” notice — a procedural event that typically precedes material announcements and can cause short‑term volume/volatility without indicating direction. (Reported earlier today.)
Neutral Sentiment: Unusually large options activity has been reported in MRUS recently; such flows often reflect speculative positioning or hedging and tend to increase intraday volatility but are ambiguous for price direction. Options Flow Report
Negative Sentiment: Reports indicate Merus has completed a Genmab acquisition and will delist from Nasdaq — a material corporate action that can reduce public float/liquidity and prompt re‑pricing or forced selling by some investors; that development is a likely contributor to the pullback in the stock. TipRanks: Acquisition/Delisting

Analyst Upgrades and Downgrades

MRUS has been the subject of a number of analyst reports. Canaccord Genuity Group lowered shares of Merus from a “buy” rating to a “hold” rating and boosted their target price for the company from $67.00 to $97.00 in a research note on Monday, September 29th. Leerink Partnrs downgraded Merus from a “strong-buy” rating to a “hold” rating in a research report on Sunday, October 5th. Guggenheim restated a “neutral” rating and issued a $97.00 target price (down from $109.00) on shares of Merus in a research report on Tuesday, September 30th. William Blair downgraded Merus from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 29th. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $97.00 price target on shares of Merus in a research note on Friday, October 31st. Three equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Merus presently has an average rating of “Hold” and a consensus target price of $93.56.

View Our Latest Research Report on Merus

Merus Company Profile

(Get Free Report)

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.